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Background
The efficacy of Infliximab and Ciclosporin for treating
moderate to severe ulcerative colitis is proven, but their
relative effectiveness has not been evaluated. There is
also limited understanding of patients’ and professionals’
views of the drugs.
Aim
The COmparison Of iNfliximab and ciclosporin in STer-
oid Resistant Ulcerative Colitis Trial (CONSTRUCT)
aimed to compare the clinical and cost effectiveness of
infliximab and ciclosporin in the treatment of steroid
resistant acute severe ulcerative colitis, using quantitative,
qualitative, and health economic data. The qualitative ele-
ment explored patients’ and health professionals’ views of
the two drugs.
Method
Within a UK multi-centre open label pragmatic rando-
mised controlled trial, 35 interviews were conducted with
20 patients and 23 health professionals involved in the
trial.
Findings
There was no significant difference between the two drugs
in clinical effectiveness terms, incidence of serious side
effects, colectomy rates or mortality. Overall, service costs
were significantly greater with infliximab, but it was
viewed more positively by patients and nurses, who dis-
liked the inconvenience of ciclosporin infusions. Health-
care professionals described the need for nurses with
special knowledge of using ciclosporin for ease of drug
handling.
Conclusion
Integrated interview data with other datasets allowed us
to bring additional insights about the impact of treat-
ment and subjective benefits and disbenefits of the
drugs to this trial. We could also describe context-speci-
fic preferences for the drugs from those directly respon-
sible for patient care, offering an added dimension to
clarifying decision-making in patient care, thus enabling
a more holistic approach to interventional drug
treatments.
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